Breakthrough study could end treatment ban for new moms with malaria
NCT ID NCT07060404
Summary
This study aims to find out if two common malaria drugs, primaquine and tafenoquine, are safe for breastfeeding mothers and their babies. Currently, these drugs are not recommended for new mothers for six months after birth due to safety concerns. Researchers will measure how much of the drugs pass into breast milk and check the health of both mothers and infants to see if earlier treatment is possible. If safe, this could allow more women to receive complete malaria treatment, preventing dangerous relapses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG PHARMACOKINETICS IN HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alexishafen Health Centre
Madang, Madang Province, MP511, Papua New Guinea
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.